1. 首頁 > 健康養生 > >

深耕細作，以HER2為靶點的ADC藥物在晚期胃癌的廣泛探索( 五 )

健康知識養生常識


[15]Thuss-PatiencePC,ShahMA,OhtsuA,etal.TrastuzumabemtansineversustaxaneuseforpreviouslytreatedHER2-positivelocallyadvancedormetastaticgastricorgastro-oesophagealjunctionadenocarcinoma(GATSBY):aninternationalrandomised,open-label,adaptive,phase2/3study.LancetOncol.2017May;18(5):640-653.
[16]PanowskiS,BhaktaS,RaabH,etal.Site-specificantibodydrugconjugatesforcancertherapy.MAbs.2014Jan-Feb;6(1):34-45.
[17]YaoX,JiangJ,WangX,etal.Anovelhumanizedanti-HER2antibodyconjugatedwithMMAEexertspotentanti-tumoractivity.BreastCancerResTreat.2015Aug;153(1):123-133.
[18]SkidmoreL,SakamuriS,KnudsenNA,etal.ARX788,aSite-specificAnti-HER2Antibody-DrugConjugate,DemonstratesPotentandSelectiveActivityinHER2-lowandT-DM1-resistantBreastandGastricCancers.MolCancerTher.2020Sep;19(9):1833-1843.
[19]肖禮海,夏鋼,王堅成.抗體偶聯藥物在胃癌治療中的研究與思考[J].生物醫學轉化,2022,3(01):20-31.
[20]ShitaraK,IwataH,TakahashiS,etal.Trastuzumabderuxtecan(DS-8201a)inpatientswithadvancedHER2-positivegastriccancer:adose-expansion,phase1study.LancetOncol.2019Jun;20(6):827-836.
[21]ShitaraK,BangYJ,IwasaS,etal;DESTINY-Gastric01Investigators.TrastuzumabDeruxtecaninPreviouslyTreatedHER2-PositiveGastricCancer.NEnglJMed.2020Jun18;382(25):2419-2430.
[22]Trastuzumabderuxtecan(T-DXd;DS-8201)inpatientswithHER2–positiveadvancedgastricorgastroesophagealjunction(GEJ)adenocarcinoma:Finaloverallsurvival(OS)resultsfromarandomized,multicenter,open-label,phase2study(DESTINY-Gastric01).2022ASCOGIAbstract.242.
[23]Trastuzumabderuxtecan(T-DXd;DS-8201)inpatientswithHER2-low,advancedgastricorgastroesophagealjunction(GEJ)adenocarcinoma:ResultsoftheexploratorycohortsinthephaseII,multicenter,open-labelDESTINY-Gastric01study.2020ESMOMiniOral1422.
[24]https://clinicaltrials.gov/
[25]UpdatedanalysisofDESTINY-GASTRIC02:aphase2single-armtrialoftrastuzumabderuxtecan(T-DXd)inwesternpatientswithHER2-posotiveunresectable/metastaticgastric/gastroesophagealjunction(GEJ)cancerwhoprogressedonoraftertrastuzumab-containingregimen.2022ESMO.AbstractMO1025.
[26]Dose-escalationanddose-expansionstudyoftrastuzumabderuxtecan(T-DXd)monotherapyandcombinationsinpatients(pts)withadvanced/metastaticHER2+gastriccancer(GC)/gastroesophagealjunctionadenocarcinoma(GEJA):DESTINY-Gastric03.2022ASCOGI.Abstract295.
[27]Phase2studyoftrastuzumabderuxtecanintheneoadjuvanttreatmentforpatientswithHER2-positivegastricandgastroesophagealjunctionadenocarcinoma(EPOC2003).2022ASCO.AbstractTPS4161.
[28]XuY,WangY,GongJ,etal.PhaseIstudyoftherecombinanthumanizedanti-HER2monoclonalantibody-MMAEconjugateRC48-ADCinpatientswithHER2-positiveadvancedsolidtumors.GastricCancer2021;24:913-925.
[29]PengZ,LiuT,WeiJ,etal.Efficacyandsafetyofanovelanti-HER2therapeuticantibodyRC48inpatientswithHER2-overexpressing,locallyadvancedormetastaticgastricorgastroesophagealjunctioncancer:asingle-armphaseIIstudy.CancerCommun(Lond).2021Nov;41(11):1173-1182.
[30]http://www.chinadrugtrials.org.cn/index.html
[31]ZhangY,QiuMZ,WangJF,etal.Phase1multicenter,dose-expansionstudyofARX788asmonotherapyinHER2-positiveadvancedgastricandgastroesophagealjunctionadenocarcinoma.CellRepMed.2022Nov15;3(11):100814.
*"醫學界"力求所發表內容專業、可靠 ， 但不對內容的準確性做出承諾；請相關各方在采用或以此作為決策依據時另行核查 。